Ignite Creation Date:
2025-12-25 @ 12:16 AM
Ignite Modification Date:
2026-01-04 @ 2:02 AM
Study NCT ID:
NCT00866658
Status:
COMPLETED
Last Update Posted:
2016-10-11
First Post:
2009-03-19
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin +/- Sulfonylurea (GETGOAL-L-ASIA)
Sponsor:
Sanofi
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2009-03
Start Date Type:
None
Primary Completion Date:
2010-06
Primary Completion Date Type:
ACTUAL
Completion Date:
2010-06
Completion Date Type:
ACTUAL
First Submit Date:
2009-03-19
First Submit QC Date:
None
Study First Post Date:
2009-03-20
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2016-08-18
Results First Submit QC Date:
None
Results First Post Date:
2016-10-11
Results First Post Date Type:
ESTIMATED
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
2012-02-23
Disp First Post Date Type:
ESTIMATED
Last Update Submit Date:
2016-08-18
Last Update Post Date:
2016-10-11
Last Update Post Date Type:
ESTIMATED